Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Zhen Qin"'
Autor:
Jing Liu, Yi-Fei Cheng, Yu-Hong Chen, Feng-Rong Wang, Huan Chen, Lan-Ping Xu, Wei Han, Jing-Zhi Wang, Xiao-Hui Zhang, Xiao-Dong Mo, Xiao-Su Zhao, Ya-Zhen Qin, Xiao-Jun Huang, Yu Wang, Kai-Yan Liu, Chen-Hua Yan
Publikováno v:
Annals of Hematology. 100:1267-1281
The prognosis of 11q23/KMT2A-rearranged (KMT2A-r) acute leukemia (AL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is poor. Minimal residual disease (MRD) is an important prognostic factor for relapse. Thus, we aimed to identi
Autor:
Jinsong Jia, Jing Wang, Hao Jiang, Ying-Jun Chang, Wenbing Duan, Lizhong Gong, Lan-Ping Xu, Xiaohong Liu, Xiao-Su Zhao, Hong-Xia Shi, Ting Zhao, Xiao-Hui Zhang, Ya-Zhen Qin, Yu Wang, Qian Jiang, Xiao-Jun Huang, Kai-Yan Liu
Publikováno v:
Annals of Hematology. 100:1203-1212
Core binding factor acute myeloid leukemia (CBF-AML), including cases with KIT mutation, is currently defined as a low-risk AML. However, some patients have poor response to treatment, and the prognostic significance of KIT mutation is still controve
Autor:
Xiao-Jun Huang, Qian Jiang, Ying-Jun Chang, Hao Jiang, Meng-Ge Gao, Yan-Rong Liu, Ya-Zhen Qin, Xiao-Su Zhao, Guo-Rui Ruan
Publikováno v:
Annals of Hematology. 99:73-82
For acute myeloid leukemia (AML) with nucleophosmin 1 mutation (NPM1m), multiparameter flow cytometry (FCM) and real-time quantitative polymerase chain reaction (RQ-PCR) are used to monitor minimal residual disease (MRD). However, the results of the
Autor:
Xiao-Hui Zhang, Lan-Ping Xu, Xiao-Jun Huang, Yan Hong, Songhai Zhou, Ya-Zhen Qin, Xiao-Su Zhao, Ying-Jun Chang, Yu Wang
Publikováno v:
Annals of Hematology. 97:1547-1554
The E2A-PBX1 rearrangement is common in B cell acute lymphoblastic leukemia (B-ALL). However, whether this fusion gene can be used as a reliable marker for minimal residual disease (MRD) following allogeneic hematopoietic stem cell transplantation (a
Autor:
Wei Han, Jing-Zhi Wang, Xiao-Hui Zhang, Yao Chen, Ya-Zhen Qin, Xiao-Dong Mo, Kai-Yan Liu, Lan-Ping Xu, Yu-Hong Chen, Ying-Jun Chang, Feng-Rong Wang, Xiao-Jun Huang, Huan Chen, Xiao-Su Zhao, Yu Wang
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-9 (2017)
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-9 (2017)
Background The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients wit
Autor:
Yan-Rong Liu, Yu Wang, Xiao-Su Zhao, Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan Liu, Ya-Zhen Qin, Chen-Hua Yan, Lan-Ping Xu
Publikováno v:
Annals of Hematology. 92:1111-1119
3065 Introduction: Current studies suggest that monitoring the minimal residual disease (MRD) of patients with malignant hematological disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is helpful for screening patients at h
Autor:
Zhengfan Jiang, Feng Wang, Xu Zhang, Xiao-Jun Huang, Ying-Jun Chang, Xiao-Ying Qin, Wei Han, Huanjun Chen, Yangyuan Wang, L P Xu, G.-X. Li, Ya-Zhen Qin, Liu Ky, Jin Wang
Publikováno v:
Journal of Translational Medicine
Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been established as an effective treatment for patients with hematological malignancies. Disease relapse remains a major cause of transplant failure. T cell homeostasis is